Key facts
- UPB - Upstream Bio, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: -$46,571.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of Upstream Bio, Inc.
- Symbol
- UPB on Nasdaq
- Location
- Waltham, MA
Change
- Buy value: ; sell value: $46,570.
- Net share flow: -5,013.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$46,571.
Buys
$0
Shares: 0
Insiders: 0
Sells
$46,571
Shares: 5,013
Insiders: 5
Net
-$46,571
Shares: -5,013
Insiders: -5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 5,013 | $0 | $46,571 | -$46,571 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Upstream Bio, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | $677,306 | -$19,444 | -2.8% | Filing P/S | 16 Mar 2026 |
| Aaron Deykin | Chief Medical Officer | $303,662 | -$8,305 | -2.7% | Filing P/S | 16 Mar 2026 |
| Michael Gray | CFO and COO | $275,429 | -$7,915 | -2.8% | Filing P/S | 16 Mar 2026 |
| Adam Houghton | Chief Business Officer | $225,756 | -$6,494 | -2.8% | Filing P/S | 16 Mar 2026 |
| Allison Ambrose | General Counsel | $153,517 | -$4,413 | -2.8% | Filing P/S | 16 Mar 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Liam Ratcliffe | Director | Mixed | 10 Jun 2025 | |||
| Marcella K. Ruddy | Director | Mixed | 10 Jun 2025 | |||
| Daniella Beckman | Director | Mixed | 10 Jun 2025 | |||
| AI Upstream LLC | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Erez Chimovits | Director | Mixed | 10 Jun 2025 | |||
| Harold Edward Fleming | Director | Mixed | 10 Jun 2025 | |||
| Ronald C. Renaud Jr. | Director | Mixed | 10 Jun 2025 |
Top shareholders of Upstream Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
|
Company |
15%
|
7,936,880
|
$93,972,663 | +$9,006,605 | 30 Jun 2025 | |
| NORGES BANK |
13D/G
|
— |
5.3%
|
2,882,647
|
$54,226,626 | $0 | 30 Sep 2025 | |
| Decheng Capital Global Life Sciences Fund IV, L.P. |
13D/G
|
— |
5%
|
2,724,868
|
$25,886,246 | -$5,324,038 | 31 Mar 2026 | |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
— |
4.1%
|
2,195,111
|
$41,290,257 | -$9,780,217 | 30 Sep 2025 | |
| TCG Crossover GP I, LLC |
13D/G
|
— |
3.9%
|
2,117,103
|
$39,822,919 | -$12,878,523 | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director, 10%+ Owner |
10%
|
5,693,589
|
$51,242,301 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
3,370,689
|
$30,336,201 | — | 31 Mar 2026 | |
| Decheng Capital LLC |
13F
|
Company |
5%
|
2,724,868
|
$24,523,812 | — | 31 Mar 2026 | |
| Enavate Sciences GP, LLC |
13F
|
Company |
4.5%
|
2,459,703
|
$22,137,327 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.4%
|
1,873,574
|
$16,862,166 | — | 31 Mar 2026 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
1.8%
|
1,000,631
|
$9,005,679 | — | 31 Mar 2026 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1.8%
|
979,758
|
$8,817,822 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
950,617
|
$8,557,453 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.7%
|
937,323
|
$8,435,907 | — | 31 Mar 2026 | |
| SEB Asset Management AB |
13F
|
Company |
1.6%
|
878,473
|
$7,906,247 | — | 31 Mar 2026 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
1.6%
|
867,211
|
$7,804,899 | — | 31 Mar 2026 | |
| Woodline Partners LP |
13F
|
Company |
1.5%
|
831,481
|
$7,483,329 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.5%
|
820,480
|
$7,384,320 | — | 31 Mar 2026 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.4%
|
786,783
|
$7,081,047 | — | 31 Mar 2026 | |
| Samsara BioCapital, LLC |
13F
|
Company |
1.4%
|
736,047
|
$6,624,423 | — | 31 Mar 2026 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.3%
|
733,431
|
$6,600,879 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
1.3%
|
727,711
|
$6,549,399 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
705,350
|
$6,348,150 | — | 31 Mar 2026 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
1.2%
|
640,326
|
$5,762,934 | — | 31 Mar 2026 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.1%
|
619,321
|
$5,573,889 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
1%
|
552,609
|
$4,973,481 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.85%
|
463,001
|
$4,065,149 | — | 31 Mar 2026 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.73%
|
400,000
|
$3,600,000 | — | 31 Mar 2026 | |
| Altshuler Shaham Ltd |
13F
|
Company |
0.7%
|
380,061
|
$3,420,549 | — | 31 Mar 2026 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.66%
|
358,000
|
$3,222,000 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.63%
|
342,353
|
$3,081,177 | — | 31 Mar 2026 | |
| Propel Bio Management, LLC |
13F
|
Company |
0.63%
|
341,779
|
$3,100,127 | — | 31 Mar 2026 | |
| Jump Financial, LLC |
13F
|
Company |
0.59%
|
319,400
|
$2,874,600 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.58%
|
316,587
|
$2,849,283 | — | 31 Mar 2026 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.55%
|
298,329
|
$2,684,961 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.48%
|
260,992
|
$2,348,928 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.47%
|
257,729
|
$2,319,561 | — | 31 Mar 2026 | |
| Prosight Management, LP |
13F
|
Company |
0.44%
|
241,123
|
$2,170,107 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.42%
|
231,254
|
$2,081,286 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.41%
|
224,157
|
$2,017,413 | — | 31 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0.38%
|
209,277
|
$1,883,493 | — | 31 Mar 2026 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.34%
|
185,087
|
$1,665,783 | — | 31 Mar 2026 | |
| TCG Crossover Management, LLC |
13F
|
Company |
0.33%
|
181,063
|
$1,629,567 | — | 31 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.33%
|
180,889
|
$1,628,001 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.33%
|
178,168
|
$1,603,512 | — | 31 Mar 2026 | |
| Trexquant Investment LP |
13F
|
Company |
0.32%
|
176,657
|
$1,589,913 | — | 31 Mar 2026 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.3%
|
161,349
|
$1,452,141 | — | 31 Mar 2026 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.28%
|
150,000
|
$1,350,000 | — | 31 Mar 2026 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.23%
|
126,000
|
$1,134,000 | — | 31 Mar 2026 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.17%
|
91,431
|
$822,879 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Upstream Bio, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Gray | UPB | Common Stock | Sale | -2.79% | $7,915 | $9.29 | -852 | 29,648 | 16 Mar 2026 | Direct |
| Aaron Deykin | UPB | Common Stock | Sale | -2.66% | $8,305 | $9.29 | -894 | 32,687 | 16 Mar 2026 | Direct |
| Everett Rand Sutherland | UPB | Common Stock | Sale | -2.79% | $19,444 | $9.29 | -2,093 | 72,907 | 16 Mar 2026 | Direct |
| Allison Ambrose | UPB | Common Stock | Sale | -2.79% | $4,413 | $9.29 | -475 | 16,525 | 16 Mar 2026 | Direct |
| Adam Houghton | UPB | Common Stock | Sale | -2.8% | $6,494 | $9.29 | -699 | 24,301 | 16 Mar 2026 | Direct |
| Michael Gray | UPB | Common Stock | Award | 30,500 | 30,500 | 02 Jan 2026 | Direct | |||
| Michael Gray | UPB | Stock Option (Right to Buy) | Award | 91,500 | 91,500 | 02 Jan 2026 | Direct | |||
| Aaron Deykin | UPB | Common Stock | Award | 2024% | 32,000 | 33,581 | 02 Jan 2026 | Direct | ||
| Aaron Deykin | UPB | Stock Option (Right to Buy) | Award | 96,000 | 96,000 | 02 Jan 2026 | Direct | |||
| Allison Ambrose | UPB | Common Stock | Award | 17,000 | 17,000 | 02 Jan 2026 | Direct | |||
| Allison Ambrose | UPB | Stock Option (Right to Buy) | Award | 51,000 | 51,000 | 02 Jan 2026 | Direct | |||
| Adam Houghton | UPB | Common Stock | Award | 25,000 | 25,000 | 02 Jan 2026 | Direct | |||
| Adam Houghton | UPB | Stock Option (Right to Buy) | Award | 75,000 | 75,000 | 02 Jan 2026 | Direct | |||
| Everett Rand Sutherland | UPB | Common Stock | Award | 75,000 | 75,000 | 02 Jan 2026 | Direct | |||
| Everett Rand Sutherland | UPB | Stock Option (Right to Buy) | Award | 225,000 | 225,000 | 02 Jan 2026 | Direct | |||
| Ronald C. Renaud Jr. | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Erez Chimovits | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Marcella K. Ruddy | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Daniella Beckman | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Harold Edward Fleming | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Liam Ratcliffe | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.